Annual Safety Report GODIF trial

EudraCT number/EU CT no	**2019-004292-40/2024-512186-14-00**
Clinical Trial Title	**Goal directed fluid removal with furosemide in intensive care patients with fluid overload – A randomised, blinded, placebo-controlled trial (GODIF).**
Sponsor	**Morten Bestle**
Designated reporter	**Sine Wichmann**
Date of the initial authorisation	**February 29, 2020**

Period of reporting: January 1, 2024, to December 31, 2024.

The trial is international, with one site in Switzerland outside the EU. In compliance with the guidelines, this report includes data exclusively from EU countries. A separate report will be prepared for submission to the Swiss authorities.

SAR in the period of reporting: Number of included patients in 2024. Number of SARs: 2
Number of patients with SARs: 2

SUSAR in the period of reporting: 0 SUSAR.

Conclusions on observed SAR/SUSAR:
The number of patients with one or more of the following SARS:

1 Severe electrolyte disturbance (p-K < 2.5 mmol/L, p-Na < 120 mmol/L, p-Cl < 90 mmol/L)
0 Aplastic anaemia
0 Agranulocytosis
0 Pancreatitis
1 Circulatory collapse leading to cardiac arrest
0 Seizures because of furosemide-induced low calcium or magnesium
0 Steven Johnson syndrome
0 Toxic epidermal necrolysis
0 Hearing impairment/loss
0 Anaphylaxis

One participant experienced low chloride in the blood with measurements down to 87 mmol/L. The patient did not experience any symptoms. The low plasma chloride was monitored closely and spontaneously

resolved without any treatment. The incident with low chloride did not affect the trial intervention, which was assessed safe to continue.

One participant experienced multiple episodes of asystole on three separate days, each lasting 10–15 seconds. All episodes resolved spontaneously without requiring intervention. The patient had several similar episodes before enrollment in the trial which was attributed to the participant's Guillain-Barré syndrome. The events were assessed as unrelated to the trial drug or intervention, and the participant remained in the trial.

The listed SARs to the trial drug (furosemide/placebo) are documented each day for all patients without the clinicians deciding on a causal relationship between the trial drug and the SARs observed.

Benefit-risk evaluation:
The reported cases did not raise any new safety concerns, as all patients are closely monitored in the Intensive Care department. The risks and benefits for the patients are considered unchanged.

Implication for the clinical trial population:

Change in /amendment to the protocol	☐ YES	☒ NO
Change in study procedures	☐ YES	☒ NO
Change in patient information	☐ YES	☒ NO
Change in informed consent form	☐ YES	☒ NO

Date: 28/1-2025 **Signature**:



Morten H. Bestle